Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
| العنوان: | Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration |
|---|---|
| المؤلفون: | Elona Dhrami-Gavazi, K. Bailey Freund, Jesse T McCann, Quraish Ghadiali, Chandrakumar Balaratnasingam |
| المصدر: | Clinical Ophthalmology (Auckland, N.Z.) |
| بيانات النشر: | Dove Medical Press, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | medicine.medical_specialty, genetic structures, Angiogenesis, Review, choroidal neovascularization, chemistry.chemical_compound, Ophthalmology, Age related, medicine, age-related macular degeneration, Aflibercept, vascular endothelial growth factor, business.industry, aflibercept, clinical trial, Macular degeneration, medicine.disease, eye diseases, Clinical trial, Vascular endothelial growth factor, Choroidal neovascularization, chemistry, Tolerability, sense organs, medicine.symptom, business, medicine.drug |
| الوصف: | Choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) is an important cause of visual morbidity globally. Modern treatment strategies for neovascular AMD achieve regression of CNV by suppressing the activity of key growth factors that mediate angiogenesis. Vascular endothelial growth factor (VEGF) has been the major target of neovascular AMD therapy for almost two decades, and there have been several intravitreally-administered agents that have enabled anatomical restitution and improvement in visual function with continual dosing. Aflibercept (EYLEA(®)), initially named VEGF Trap-eye, is the most recent anti-VEGF agent to be granted US Food and Drug Administration approval for the treatment of neovascular AMD. Biologic advantages of aflibercept include its greater binding affinity for VEGF, a longer intravitreal half-life relative to other anti-VEGF agents, and the capacity to antagonize growth factors other than VEGF. This paper provides an up-to-date summary of the molecular mechanisms mediating CNV. The structural, pharmacodynamic, and pharmacokinetic advantages of aflibercept are also reviewed to rationalize the utility of this agent for treating CNV. Results of landmark clinical investigations, including VIEW 1 and 2 trials, and other important studies are then summarized and used to illustrate the efficacy of aflibercept for managing treatment-naive CNV, recalcitrant CNV, and CNV due to polypoidal choroidal vasculopathy. Safety profile, patient tolerability, and quality of life measures related to aflibercept are also provided. The evidence provided in this paper suggests aflibercept to be a promising agent that can be used to reduce the treatment burden of neovascular AMD. |
| اللغة: | English |
| تدمد: | 1177-5483 1177-5467 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8453152f33d38a2bdd95679a1a2f669Test http://europepmc.org/articles/PMC4689264Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c8453152f33d38a2bdd95679a1a2f669 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 11775483 11775467 |
|---|